SCHEDULE 13G/A: Farallon Capital Group Discloses 8.8% Passive Stake in Lantheus Holdings, Inc.

Farallon Capital and its affiliated entities have filed an amended Schedule 13G, revealing a collective passive beneficial ownership of 8.8% in Lantheus Holdings, Inc.'s common stock as of March 31, 2025.

Summary

• Farallon Capital Partners, L.P., along with several affiliated funds and general partners (collectively, the "Farallon Funds"), and their managing members/senior managing members, have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership of Lantheus Holdings, Inc. (Shares).
• The filing indicates that the Farallon group, through various entities and individuals, collectively holds shared voting and dispositive power over 6,023,227 shares of Lantheus Holdings, Inc. common stock.
• This aggregate beneficial ownership represents 8.8% of the outstanding common stock of Lantheus Holdings, Inc.
• The largest individual fund holding is by Farallon Healthcare Partners Master, L.P., with 3,465,283 shares, representing 5.1% of the class.
• Farallon Partners, L.L.C., as the general partner for several funds, reports beneficial ownership of 5,863,954 shares, or 8.6% of the class.
• The individual managing members and senior managing members of Farallon Capital Management, L.L.C. are deemed beneficial owners of the aggregate 6,023,227 shares, representing 8.8% of the class.
• The filing certifies that the securities were not acquired and are not held for the purpose or effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or outlook. It is a neutral regulatory filing.

Future Outlook

NA

Industry Context

This filing indicates a significant passive investment by a prominent hedge fund, Farallon Capital, in Lantheus Holdings, Inc., a company operating in the healthcare sector. Such disclosures are common for institutional investors accumulating stakes in publicly traded companies, reflecting their investment thesis on the company's future prospects within its industry.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Farallon Capital may be viewed positively by some investors as a vote of confidence, potentially influencing market perception and trading activity.
• Company Management: Awareness of a large passive institutional investor may influence management's strategic decisions, though the filing explicitly states no intent to influence control.

Key Dates

Keywords

Lantheus Holdings Inc., Farallon Capital, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing, Healthcare, Pharmaceuticals